Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion type Assertion NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_head.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion wasGeneratedBy ECO_0000203 NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion wasDerivedFrom befree-20150227 NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion SIO_000772 23760401 NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion evidence source_evidence_literature NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.
- NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278807.RAiyOP7ixc2OmwAYOf1QRzvso1SnSfmXVQCmZBGuFCl0o130_provenance.